Dyadic International (DYAI) Research & Development (2018 - 2026)
Dyadic International (DYAI) posted Research & Development of $476069.0 for Q1 2026, up 3.85% sequentially from $458436.0 in Q4 2025, and down 3.82% YoY from $494979.0 in Q1 2025.
Dyadic International (DYAI) Research & Development (2018 - 2026) Analysis & Trends
Dyadic International has reported Research & Development for 9 years, with the latest figure at $476069.0 in Q1 2026.
- Quarterly Research & Development fell 3.82% year-over-year to $476069.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 5.91% YoY) and the FY2025 annual result came in at $2.2 million, up 5.4% from the prior year.
- Research & Development climbed to $476069.0 in Q1 2026 per DYAI's latest filing, from $458436.0 in the prior quarter.
- Over five years, Research & Development peaked at $1.8 million in Q2 2022 and troughed at $458436.0 in Q4 2025.
- A 5-year average of $743093.7 and a median of $600625.5 in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development sank 99.93% in 2022, then climbed 24.25% in 2025.
- Over 5 years, Research & Development stood at $743585.0 in 2022, then grew by 14.69% to $852797.0 in 2023, then plunged by 36.02% to $545660.0 in 2024, then decreased by 15.99% to $458436.0 in 2025, then gained by 3.85% to $476069.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $476069.0, $458436.0, and $571872.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 476,069.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 476,069.00 |
| Dec 31, 2025 | 458,436.00 |
| Sep 30, 2025 | 571,872.00 |
| Jun 30, 2025 | 629,379.00 |
| Mar 31, 2025 | 494,979.00 |
| Dec 31, 2024 | 545,660.00 |
| Sep 30, 2024 | 460,241.00 |
| Jun 30, 2024 | 515,629.00 |
| Mar 31, 2024 | 522,723.00 |
| Dec 31, 2023 | 852,797.00 |
| Sep 30, 2023 | 716,351.00 |
| Jun 30, 2023 | 917,552.00 |
| Mar 31, 2023 | 810,566.00 |
| Sep 30, 2022 | 743,585.00 |
| Jun 30, 2022 | 1.83 Mn |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 2.47 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Jun 30, 2021 | 2.21 Bn |
| Mar 31, 2021 | 1.81 Bn |